Proteon Therapeutics

American pharmaceutical company

TARA Nasdaq SEC CIK 1359931
Follow Proteon Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$21.7M −63.6% vs same quarter last year
EPS, diluted −$0.35 −12.9% vs same quarter last year
Operating cash flow −$18.4M −48.1% vs same quarter last year
Operating income −$23.2M −56.9% vs same quarter last year
Net income by quarter
−$12.8M
−$11.9M
−$15M
−$13.3M
−$17.3M
−$17.8M
−$21.7M
−$21.7M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
−$80M−$60M−$40M−$20M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearNet income
FY25−$57.4M
FY24−$44.6M
FY23−$40.4M
FY22−$66M
FY21−$47.3M
FY20−$34M
FY19−$7.8M
FY18−$20.7M
FY17−$30M
FY16−$28.5M
FY15−$21.4M
FY14−$3.3M
FY13−$7.9M
FY12−$8M
FY11-
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$56.5M
FY24−$35.9M
FY23−$37.6M
FY22−$26.6M
FY21−$35.1M
FY20−$24.3M
FY19−$5.5M
FY18−$23.4M
FY17−$22.4M
FY16−$24M
FY15−$17.8M
FY14−$10M
FY13−$6.7M
FY12−$8.3M
FY11-
Returned to shareholdersDividends paid and shares bought back
$0$100K$200K$300KFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearBuybacks
FY25-
FY24-
FY23$91K
FY22$90K
FY21$228K
FY20-
FY19-
FY18-
FY17-
FY16-
FY15-
FY14-
FY13-
FY12-
FY11-